Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;27(Suppl 2):243S–247S. doi: 10.1111/j.1365-2125.1989.tb03488.x

The effect of acute ACE inhibition on atrial natriuretic peptide

C J Doorenbos, P Van Brummelen
PMCID: PMC1379754  PMID: 2527537

Abstract

1 The effect of acute angiotensin converting enzyme (ACE) inhibition on the plasma concentrations of atrial natriuretic peptide (ANP) was investigated in a single-blind placebo controlled crossover study in healthy volunteers.

2 Intravenous infusion of 2 mg cilazaprilat resulted in a significant and short lasting inhibition of ACE as evidenced by a decrease of plasma angiotensin II and an increase in plasma renin activity.

3 When compared with placebo cilazaprilat lowered diastolic pressure and increased heart rate significantly.

4 No effect of cilazaprilat was found on plasma ANP levels, suggesting that angiotensin II does not mediate ANP release.

Keywords: atrial natriuretic peptide, angiotensin converting enzyme inhibition cilazaprilat

Full text

PDF
243S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chalmers J. P., Wing L. M., West M. J., Bune A. J., Elliott J. M., Morris M. J., Cain M. D., Graham J. R., Southgate D. O. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust N Z J Med. 1986 Aug;16(4):475–480. doi: 10.1111/j.1445-5994.1986.tb02014.x. [DOI] [PubMed] [Google Scholar]
  2. Gaillard C. A., Koomans H. A., Mees E. J. Enalapril attenuates natriuresis of atrial natriuretic factor in humans. Hypertension. 1988 Feb;11(2):160–165. doi: 10.1161/01.hyp.11.2.160. [DOI] [PubMed] [Google Scholar]
  3. Hansell P., Ulfendahl H. R. Effects of atrial natriuretic peptide (ANP) during converting enzyme inhibition. Acta Physiol Scand. 1987 Jul;130(3):393–399. doi: 10.1111/j.1748-1716.1987.tb08154.x. [DOI] [PubMed] [Google Scholar]
  4. Higuchi K., Nawata H., Kato K., Ibayashi H., Matsuo H. Alpha-human atrial natriuretic polypeptide inhibits steroidogenesis in cultured human adrenal cells. J Clin Endocrinol Metab. 1986 May;62(5):941–944. doi: 10.1210/jcem-62-5-941. [DOI] [PubMed] [Google Scholar]
  5. Hirata Y., Ishii M., Sugimoto T., Matsuoka H., Ishimitsu T., Atarashi K., Sugimoto T., Miyata A., Kangawa K., Matsuo H. Relationship between the renin-aldosterone system and atrial natriuretic polypeptide in rats. Clin Sci (Lond) 1987 Feb;72(2):165–170. doi: 10.1042/cs0720165. [DOI] [PubMed] [Google Scholar]
  6. Hughes A., Thom S., Goldberg P., Martin G., Sever P. Direct effect of alpha-human atrial natriuretic peptide on human vasculature in vivo and in vitro. Clin Sci (Lond) 1988 Feb;74(2):207–211. doi: 10.1042/cs0740207. [DOI] [PubMed] [Google Scholar]
  7. Iwao H., Fukui K., Yamamoto A., Shoji T., Abe Y. Effects of captopril on plasma atrial natriuretic polypeptide and the renin angiotensin system in rats. Clin Exp Hypertens A. 1987;9(2-3):697–701. doi: 10.3109/10641968709164245. [DOI] [PubMed] [Google Scholar]
  8. Katz F. H., Romfh P., Smith J. A. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab. 1975 Jan;40(1):125–134. doi: 10.1210/jcem-40-1-125. [DOI] [PubMed] [Google Scholar]
  9. Kohno M., Yasunari K., Matsuura T., Kanayama Y., Takaori K., Murakawa K., Takeda T. Effect of chronic treatment with angiotensin I converting enzyme inhibitors on circulating atrial natriuretic polypeptide in spontaneously hypertensive rats. Clin Exp Hypertens A. 1987;9(2-3):693–696. doi: 10.3109/10641968709164244. [DOI] [PubMed] [Google Scholar]
  10. Kurtz A., Della Bruna R., Pfeilschifter J., Taugner R., Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4769–4773. doi: 10.1073/pnas.83.13.4769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Maack T., Camargo M. J., Kleinert H. D., Laragh J. H., Atlas S. A. Atrial natriuretic factor: structure and functional properties. Kidney Int. 1985 Apr;27(4):607–615. doi: 10.1038/ki.1985.54. [DOI] [PubMed] [Google Scholar]
  12. Mann F. E., Lang R. E., Leidig M., Ritz E. Effect of angiotensin I converting enzyme inhibition on circulating atrial natriuretic peptide in humans. Klin Wochenschr. 1986;64 (Suppl 6):13–15. [PubMed] [Google Scholar]
  13. Mantero F., Rocco S., Pertile F., Carpenè G., Fallo F., Leone L., Boscaro M. Effect of alpha-human atrial natriuretic peptide in low renin essential hypertension and primary aldosteronism. Clin Exp Hypertens A. 1987;9(10):1505–1513. doi: 10.3109/10641968709158999. [DOI] [PubMed] [Google Scholar]
  14. McMurray J., Struthers A. D. Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man. Clin Sci (Lond) 1988 Apr;74(4):419–425. doi: 10.1042/cs0740419. [DOI] [PubMed] [Google Scholar]
  15. Needleman P., Greenwald J. E. Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. N Engl J Med. 1986 Mar 27;314(13):828–834. doi: 10.1056/NEJM198603273141306. [DOI] [PubMed] [Google Scholar]
  16. Peuler J. D., Johnson G. A. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci. 1977 Sep 1;21(5):625–636. doi: 10.1016/0024-3205(77)90070-4. [DOI] [PubMed] [Google Scholar]
  17. Solomon L. R., Atherton J. C., Bobinski H., Green R. Effect of posture on plasma immunoreactive atrial natriuretic peptide concentrations in man. Clin Sci (Lond) 1986 Sep;71(3):299–305. doi: 10.1042/cs0710299. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES